The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

Participants in the study will receive AL8326 as a second-line treatment, which means it is given after the initial treatment has been completed. The study will explore different doses of the medication to find the best balance between effectiveness and safety. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will last for a period of up to 12 months, during which the health and response of the participants will be closely monitored.

The trial aims to determine the optimal dose of AL8326 that provides the best results for patients with SCLC. This includes looking at how well the cancer responds to the treatment and how long the benefits last. The study will also gather information on how the body processes the medication and any potential side effects. This research is important for improving treatment options for patients with Small Cell Lung Cancer who need further therapy after their initial treatment.

Participants in the study will receive either the HLX10 treatment or a placebo, alongside the standard chemotherapy and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the HLX10 or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with regular monitoring to assess the treatment’s impact on the cancer and any side effects experienced by the participants.

The main goal is to see if the combination of HLX10 with chemotherapy and radiotherapy can improve overall survival rates for patients with LS-SCLC. Secondary goals include measuring progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and the objective response rate, which is the proportion of patients whose cancer shrinks or disappears after treatment. The study will also monitor the quality of life of participants and any adverse events that occur during the trial.

The study will likely begin with small groups of people receiving BMS-986525 by intravenous infusion, either by itself or with nivolumab. The treatment is given over time, and the study team watches for side effects and other changes while treatment continues. The purpose of the study is to find the best dose for further testing and to learn how the medicines behave in the body.

Relapsed means the cancer has returned after treatment, and refractory means it has not improved with treatment. Small Cell Lung Cancer is a fast-growing type of lung cancer. This study is focused on learning more about the safety of BMS-986525 with and without nivolumab in this disease.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of this study is to evaluate the effectiveness of a drug called tarlatamab. This medication is an intravenous infusion, meaning it is delivered directly into a vein through a liquid solution. Participants in the trial will receive this treatment to see how it influences how long patients live and how the cancer responds to the medicine.

The purpose of the study is to characterize the pharmacokinetics, which describes how a drug moves through the body, specifically for the subcutaneous version of the medicine. Participants will be monitored to ensure the safety of this administration method and to see how much of the medicine stays in the bloodstream over time. During the course of the study, different doses may be used to determine the most appropriate amount for patients.

Participants in the study will receive their assigned medications through an intravenous infusion. The goal of the research is to determine the best dose of ABBV-706 to use in future larger studies and to see how well this combination works to control the disease compared to traditional therapy. The study will monitor how long the cancer remains stable without getting worse and how the body responds to the different treatment combinations.

The purpose of this study is to compare how well BNT327 works compared to atezolizumab when each is given with chemotherapy, specifically by looking at how long participants live after starting treatment. The study will also examine how long participants live without their cancer getting worse, how many participants see their tumors shrink or disappear, and how long these responses last. Additionally, the study will monitor side effects and how the treatments affect quality of life and cancer-related symptoms such as coughing and shortness of breath.

This is a randomized study, which means participants will be assigned by chance to receive either BNT327 with chemotherapy or atezolizumab with chemotherapy. The study is double-blinded, meaning neither the participants nor their doctors will know which treatment group they are in during the study. Participants will receive treatment for up to 48 weeks or longer depending on how they respond to the treatment. Throughout the study, participants will have regular visits where their health, tumor size, and any side effects will be monitored through physical examinations, blood tests, imaging scans, and questionnaires about their well-being and symptoms.

The purpose of this study is to describe the safety profile of durvalumab in patients with limited stage small cell lung cancer who have not progressed following chemoradiotherapy. Small cell lung cancer is an aggressive type of lung cancer that tends to grow and spread quickly. Limited stage means the cancer is confined to one side of the chest and can be treated with radiation therapy.

During the study, patients will receive durvalumab for a specific period after completing their chemoradiotherapy. The researchers will monitor patients for side effects, especially those related to the immune system, as durvalumab is a type of immunotherapy that works by helping the immune system recognize and attack cancer cells. They will also track how long patients live without their disease getting worse and their overall survival rate.

The purpose of this research is to test different dosing schedules of tarlatamab to determine how well it works in treating Small Cell Lung Cancer. The study will include patients whose cancer has continued to grow or has returned after receiving previous treatment with platinum-based chemotherapy. Some patients may have also received prior treatment with other cancer medications.

During the study, participants will receive tarlatamab through regular intravenous infusions. Another medication called siltuximab may also be used as part of the treatment plan. Patients will have regular check-ups and tests to monitor their health and how their cancer responds to the treatment. The study team will track various aspects of the treatment’s effectiveness, including how the cancer responds and how long these responses last.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in people whose cancer has returned or has not responded to previous treatments. The study will be conducted in two parts. In the first part, participants will receive either a combination of MK-6070 and I-DXd or I-DXd alone, to see how well these treatments are tolerated and how effective they are. In the second part, the focus will be on the safety and tolerability of MK-6070 alone in participants in Japan.

Participants in the study will receive the treatments at different times and will be monitored for any side effects or changes in their condition. The study aims to gather information on how the body responds to these treatments, including how long the treatments stay in the body and how they are processed. This information will help researchers understand the potential benefits and risks of these new treatment options for small cell lung cancer.

The purpose of the study is to assess the safety and effectiveness of AL8326 in patients who need a second or later line of treatment for Small Cell Lung Cancer. This includes patients whose cancer has spread to the brain, as long as the brain metastasis is controlled and not causing active bleeding. The study aims to find the best dose of the medication that balances effectiveness and safety.

Participants in the study will receive AL8326 and will be monitored over a period of time to observe how well the drug works and to check for any side effects. Some participants may receive a placebo for comparison. The study will help determine the optimal dose and gather information on how the drug affects the body, which will be useful for future treatments of Small Cell Lung Cancer.

The purpose of the study is to evaluate the safety and effectiveness of PF-07104091 in patients with advanced or metastatic forms of these cancers. The study will be conducted in phases, starting with determining the appropriate dosage of PF-07104091 when used alone. Subsequent phases will assess the safety and potential benefits of combining PF-07104091 with other cancer treatments. Patients will receive either the new treatment or a placebo, and their health will be monitored to understand how the treatment affects their cancer and overall well-being.

Participants in the study will take the medication orally, in the form of capsules or tablets, or receive it through an injection, depending on the specific treatment plan. The study aims to gather information on how the body processes the medication and its impact on tumor growth. This research is crucial for developing new treatment options for patients with these challenging cancer types.

The purpose of this research is to determine how safe the medication is, how it moves through the body, and how effective it is in treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to find the most appropriate amount. In the second part, researchers will evaluate how well the medication works in treating the cancer.

During the study, participants will take CYC140 once daily for 28-day cycles. The treatment will continue as long as it remains beneficial for the patient. Throughout the study, doctors will monitor patients’ health status and how their cancer responds to the treatment. Various medical assessments will be performed to track the progress of the treatment and ensure patient safety.

The purpose of the study is to see how well Ifinatamab deruxtecan works compared to chemotherapy in treating SCLC. Participants in the study will receive either Ifinatamab deruxtecan or a treatment chosen by their doctor, which may include Topotecan or other chemotherapy options. The study will monitor how the cancer responds to the treatment and how long patients live after starting the treatment. This will help researchers understand if the new treatment is more effective than the current options.

Participants will receive their assigned treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of time, during which patients will have regular check-ups to monitor their health and the progress of their cancer. The trial aims to provide valuable information that could lead to better treatment options for people with relapsed SCLC in the future.

The study will use two different treatment approaches. Some patients will receive nivolumab alone, while others will receive a combination of nivolumab and ipilimumab. Both medications are given through an intravenous infusion, which means they are delivered directly into a vein. The medications being tested are designed to boost the immune system’s ability to detect and destroy cancer cells.

During the study, doctors will monitor how patients respond to the treatment and track any side effects that may occur. The study will look at whether tumors shrink or stop growing in response to the treatment, and how long patients survive without their cancer getting worse. This research may help develop new treatment options for patients with these types of advanced cancers.

The purpose of the study is to explore whether adding atezolizumab to the standard chemotherapy can improve the overall survival of patients with SCLC. Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will follow the participants over a period to monitor their health and the progression of their cancer. Some participants may receive a placebo instead of atezolizumab to compare the effects of the treatment.

Throughout the study, researchers will assess the safety of the treatment by monitoring any side effects experienced by the participants. They will also measure how long the participants live without their cancer getting worse, known as progression-free survival, and the overall response rate, which indicates how well the cancer responds to the treatment. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of this study is to evaluate how well the combination of these drugs works in treating patients who have not yet received treatment for their ES-SCLC. Some participants will receive a placebo instead of tiragolumab to compare the outcomes. The study will monitor participants over a period of time to assess their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time from the start of treatment that patients are still alive.

Participants in the study will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will last for up to 72 weeks, during which time participants will have regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether adding tiragolumab to the treatment regimen can improve outcomes for patients with ES-SCLC.

The purpose of this study is to determine how well these treatments work together in controlling the cancer and to assess their safety. Participants in the study will receive these medications either through an intravenous infusion, which is a method of delivering medicine directly into the bloodstream, or orally in the form of capsules. The study will monitor the participants over a period to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, participants will undergo regular assessments to track the progress of their cancer and to ensure their safety. These assessments will help researchers understand the potential benefits and risks of using these combinations of treatments for patients with extensive-stage small cell lung cancer. The study is designed to provide valuable information that could lead to improved treatment options for this challenging condition.

The purpose of this study is to see how effective the combination of niraparib and anti-PD-L1 antibodies is in treating patients with this specific type of lung cancer. Patients who participate in the study will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds. The study will also compare the effects of the treatment with a placebo to better understand its benefits.

Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein, and they will also take niraparib in tablet form. The study aims to provide more information on how well this combination works in preventing the cancer from getting worse and improving overall survival rates. The results will help determine if this treatment approach can be a beneficial option for patients with this type of lung cancer.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to determine if there is a difference in overall survival between the different treatment groups. Participants will be randomly assigned to one of three groups: one group will receive lurbinectedin alone, another group will receive lurbinectedin combined with irinotecan, and the third group will receive either topotecan or irinotecan as chosen by the study investigator. The study will monitor participants over a period to assess how well the treatments work and to observe any side effects.

Throughout the study, participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study aims to provide valuable information on the potential benefits and safety of these treatments for patients with relapsed SCLC. The results could help improve future treatment options for this aggressive form of lung cancer.

The purpose of this study is to evaluate the safety and effectiveness of different doses of BI 764532 in patients whose cancer has returned or continued to grow after previous treatments. Participants in the study will receive the medication through an intravenous infusion, which means it will be given directly into a vein. The study will monitor how well the treatment works and any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, participants will have regular check-ups and assessments to track their response to the treatment. The study aims to find the most effective dose of BI 764532 that can help manage these types of cancers while ensuring the safety of the participants. The trial will provide valuable information that could lead to new treatment options for patients with these challenging cancers.

The purpose of the study is to assess how accurately the OWL-EVO1 test can identify lung cancer in people who are undergoing screening or have findings on a CT scan that might suggest lung cancer. Participants will receive the test and be monitored to see how well it works in identifying lung cancer compared to other conditions that might look similar on a scan. The study will also look at the safety and tolerability of the test, ensuring that it is safe for participants to use.

Throughout the study, participants will receive the test and be observed over a period of time to gather information on its effectiveness and safety. The study will help determine if the OWL-EVO1 test can be a reliable tool for diagnosing lung cancer, potentially leading to earlier and more accurate detection of the disease.

The purpose of the study is to see how well the 68Ga-satoreotide trizoxetan tracer is taken up by cancer cells in patients with these types of lung cancer. During the study, patients will receive an injection of the tracer, and then undergo a PET/CT scan. This scan combines the PET scan with a computed tomography or CT scan, providing detailed images of the cancer. The study will compare these images to previous scans to see if the new tracer can identify cancerous areas more effectively.

The study will also measure certain parameters in the cancerous areas, such as how much of the tracer is absorbed, and compare these measurements to those in normal organs like the lung, kidney, and liver. This will help researchers understand how well the tracer can distinguish between cancerous and non-cancerous tissues. The study is expected to continue until mid-2026.

The purpose of the study is to compare the overall survival of patients receiving these treatments. Participants will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular visits to monitor the participants’ health and response to the treatment. The study will also look at other factors, such as how long the cancer stays under control and the quality of life of the participants during the treatment.

Throughout the study, some participants will receive a saline placebo as part of the treatment process. This is a standard practice in clinical trials to help researchers understand the effects of the actual medications being tested. The trial aims to provide valuable information that could lead to better treatment options for people with extensive-stage small-cell lung cancer in the future.

Participants in the study will receive an intravenous injection of 68Ga-EVG321. After the injection, they will undergo imaging tests, such as PET/CT scans, to observe how the treatment moves and accumulates in different parts of the body, particularly in areas affected by cancer. These tests will help researchers measure the radioactivity levels in various organs and tissues over time. The study will also monitor participants for any side effects or changes in health indicators, such as lab test results, heart function, and vital signs.

The trial aims to compare the imaging results with traditional methods of diagnosing SCLC to see if 68Ga-EVG321 can provide more accurate information about the presence of cancer. By doing so, the study hopes to improve the understanding of how this diagnostic tool can be used in the future to help detect and manage Small Cell Lung Cancer more effectively.

Participants in the study will be randomly assigned to one of two groups. One group will receive atezolizumab after completing chemoradiotherapy, while the other group will continue with chemoradiotherapy alone. The study will monitor participants over a period of time to assess their overall survival, which refers to the length of time patients live after starting the treatment. Other aspects being observed include the best response to the treatment, how long patients live without the cancer getting worse (progression-free survival), any side effects (toxicity), and the impact on the patients’ quality of life.

The trial aims to provide valuable information on whether adding atezolizumab to the standard treatment can offer better outcomes for patients with limited disease small-cell lung cancer. This study is part of ongoing research to find more effective treatments for this type of cancer and to improve the lives of those affected by it.